The role of the growth hormone in assisted reproductive technologies cycles

Cover Page

Cite item

Full Text

Abstract

The paper analyzes the literature data on the use of the growth hormone (GH) in ovarian stimulation in assisted reproductive technologies (ART). Routine use of GH in ovarian stimulation in patients with a normal GH level does not increase pregnancy and childbirth rates in ART. Also, no benefits of using GH have been identified for patients with polycystic ovary syndrome, despite the increase in insulin and IGF-1 blood levels. The main research focus is to study the use of GH in patients with poor ovarian response. According to the meta-analysis conducted by X.-L. Li et al. (2017), GH in ovarian stimulation of poor ovarian responders increases the number of received oocytes, mature oocytes number, reduces the embryo transfer cancellation rate and does not affect the fertilization rate. The pregnancy and live birth rates are significantly higher in the group of GH use - by 1.65 (95% CI 1.23-2.22) and 1.73 (95% CI 1.25-2.40) times, respectively. Thus, it is advisable to use GH in ovarian stimulation in poor ovarian responders, since it allows to increases live birth rate in ART. However, further studies should determine the optimal GH dose and assesse it`s safety in ART programs.

About the authors

Andrey Y Romanov

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: romanov1553@yandex.ru
Postgraduate Student Moscow, Russia

Anastasiya G Syrkasheva

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: anast.syrkasheva@gmail.com
Cand. Sci. (Med.) Moscow, Russia

Nataliya V Dolgushina

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: n_dolgushina@oparina4.ru
D. Sci. (Med.) Moscow, Russia

Elena A Kalinina

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: e_kalinina@oparina4.ru
D. Sci. (Med.) Moscow, Russia

References

  1. Homburg R, Eshel A, Abdalla H.I, Jacobs H.S. Growth hormone facilitates ovulation induction by gonadotrophins. Clin Endocrinol (Oxf) 1988; 29 (1): 113-7.
  2. Owen E.J, West C, Mason B.A, Jacobs H.S. Co-treatment with growth hormone of sub-optimal responders in IVF-ET. Hum Reprod 1991; 6 (4): 524-8.
  3. Hart R.J, Rombauts L, Norman R.J. Growth hormone in IVF cycles: any hope? Curr Opin Obstet Gynecol 2017; 29 (3): 119-25.
  4. Menezo Y.J.R, Nicollet B, Rollet J, Hazout A. Pregnancy and delivery after in vitro maturation of naked ICSI-GV oocytes with GH and transfer of a frozen thawed blastocyst: case report. J Assist Reprod Genet 2006; 23 (1): 47-9.
  5. Bachelot A, Monget P, Imbert-Bolloré P et al. Growth hormone is required for ovarian follicular growth. Endocrinology 2002; 143 (10): 4104-12.
  6. Mendoza C, Ruiz-Requena E, Ortega E et al. Follicular fluid markers of oocyte developmental potential. Hum Reprod 2002; 17 (4): 1017-22.
  7. Oosterhuis G.J, Vermes I, Lambalk C.B et al. Insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations in fluid from human stimulated follicles. Hum Reprod 1998; 13 (2): 285-9.
  8. Mendoza C, Cremades N, Ruiz-Requena E et al. Relationship between fertilization results after intracytoplasmic sperm injection, and intrafollicular steroid, pituitary hormone and cytokine concentrations. Hum Reprod 1999; 14 (3): 628-35.
  9. Tarlatzis B.C, Pazaitou K, Bili H et al. Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction. Hum Reprod 1993; 8 (10): 1612-6.
  10. Tesarik J, Hazout A, Mendoza C. Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Hum Reprod 2005; 20 (9): 2536-41.
  11. Regan S.L.P, Knight P.G, Yovich J.L et al. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril 2018; 110 (7): 1298-310.
  12. Bassiouny Y.A, Dakhly D.M.R, Bayoumi Y.A, Hashish N.M. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril 2016; 105 (3): 697-702.
  13. Bayoumi Y.A, Dakhly D.M.R, Bassiouny Y.A, Hashish N.M. Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response. Int J Gynaecol Obstet 2015; 131 (3): 305-8.
  14. Chen Y, Liu F, Nong Y et al. Clinical efficacy and mechanism of growth hormone action in patients experiencing repeat implantation failure. Can J Physiol Pharmacol 2018; 96 (9): 929-32.
  15. Younis J.S, Simon A, Koren R et al. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study. Fertil Steril 1992; 58 (3): 575-80.
  16. Bergh C, Hillensjö T, Wikland M et al. Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertil Steril 1994; 62 (1): 113-20.
  17. Homburg R, Levy T, Ben-Rafael Z. Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial. Hum Reprod 1995; 10 (10): 2550-3.
  18. Kolibianakis E.M, Venetis C.A, Diedrich K et al. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009; 15 (6): 613-22.
  19. Kyrou D, Kolibianakis E.M, Venetis C.A et al. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009; 91 (3): 749-66.
  20. Li X-L, Wang L, Lv F et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96 (12): e6443.
  21. Meldrum D.R, Quaas A.M, Su H.I. Why is growth hormone underutilized for our most difficult IVF couples? Fertil Steril. 2018; 110 (7): 1261-2.
  22. Papathanasiou A, Searle B.J, King N.M.A, Bhattacharya S. Trends in “poor responder” research: lessons learned from RCTs in assisted conception. Hum Reprod Update 2016; 22 (3): 306-19.
  23. Сыркашева А.Г., Ильина Е.О., Долгушина Н.В. Бесплодие у женщин старшего репродуктивного возраста: причины, тактика ведения, перспективы использования преимплантационного генетического скрининга (обзор литературы). Гинекология. 2016; 18 (3): 40-3.
  24. Ванян Р.Э., Долгушина Н.В. Клинико-анамнестические факторы риска развития «бедного» овариального ответа в программах вспомогательных репродуктивных технологий. Гинекология. 2014; 16 (5): 73-7.
  25. Бейк Е.П., Сыркашева А.Г., Долгушина Н.В. Эффективность программ вспомогательных репродуктивных технологий у пациенток позднего репродуктивного возраста. Гинекология. 2018; 20 (1): 109-12.
  26. Huang Z.H, Baxter R.C, Hughes S.M et al. Supplementary growth hormone treatment of women with poor ovarian response to exogenous gonadotrophins: changes in serum and follicular fluid insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3). Hum Reprod 1993; 8 (6): 850-7.
  27. Jeve Y.B, Bhandari H.M. Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. J Hum Reprod Sci 2016; 9 (2): 70-81.
  28. Guan Q, Ma H, Wang Y, Zhang F. Effects of co-administration of growth hormone (GH) and aspirin to women during in vitro fertilization and embryo transfer (IVF-ET) cycles. Zhonghua Nan Ke Xue 2007; 13 (9): 798-800.
  29. Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J Assist Reprod Genet 2008; 25 (4): 123-7.
  30. Eftekhar M, Aflatoonian A, Mohammadian F, Eftekhar T. Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstet 2013; 287 (5): 1017-21.
  31. Møller J, Nielsen S, Hansen T.K. Growth hormone and fluid retention. Horm Res 1999; 51 (Suppl. 3): 116-20.
  32. Kokshoorn N.E, Biermasz N.R, Roelfsema F et al. GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 2011; 164 (5): 657-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).